Evidence map›Paper›PMID 40319350›Full record

ArticleThe American journal of case reports2025

Refractory Pleuritis in a Patient with Silicosis, Systemic Sclerosis, and Sjögren's Syndrome: Considering the Potential Role of Adjuvant-Induced Autoimmunity.

Julia Morimoto, Yasuhito Suzuki, Ryuichi Togawa, Natsumi Watanabe, Takahiro Kumanaka, Ryutaro Tanaka, Kentaro Kazama, Koshi Saito, Rina Harigane, Ryuki Yamada and 12 more

Abstract readCase Reports
In one paragraph

Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Julia MorimotoDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Yasuhito SuzukiDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Ryuichi TogawaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Natsumi WatanabeDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Takahiro KumanakaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Ryutaro TanakaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Kentaro KazamaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Koshi SaitoDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Rina HariganeDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Ryuki YamadaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Riko SatoDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Hikaru TomitaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Takashi UmedaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Mami RikimaruDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Yuki SatoDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Hiroyuki MinemuraDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Takefumi NikaidoDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Junpei SaitoDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.ORCID 0000-0002-9876-1160
Kenya KanazawaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.ORCID 0000-0002-9574-0516
Xintao WangDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.ORCID 0009-0009-7657-272X
Yoshinori TaninoDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.ORCID 0000-0003-2384-601X
Yoko ShibataDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.ORCID 0000-0003-1794-0026

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Silicosis, which is caused by the inhalation of crystalline silica, is known to be associated with a variety of autoimmune diseases. Recently, a new pathogenesis called autoimmune/inflammatory syndrome induced by adjuvants (ASIA) has been reported, which occurs after exposure to substances with adjuvant activity, including silica, and shares clinical features observed in several autoimmune diseases. CASE REPORT A 65-year-old man with silicosis was admitted to our hospital due to fever and chronic fatigue. Symptoms such as sicca and Raynaud's phenomenon and pleural effusion appeared as new findings on admission. Examination led to a diagnosis of systemic scleroderma (SSc) and Sjögren's syndrome (SjS). Considering that SjS was the main cause of the disease, corticosteroid therapy was initiated. However, the patient's general condition deteriorated, leading finally to his death. Silica acts as an adjuvant, inducing chronic inflammatory cytokine release. Thus, prolonged exposure to silica can contribute to the development of autoimmune diseases such as SSc and SjS. In this case, the refractory pleuritis may have been related to the pathogenesis of ASIA. ASIA is difficult to manage if the causative adjuvant cannot be eliminated. CONCLUSIONS We described a case of newly diagnosed SSc and SjS with therapy-resistant pleuritis in a patient with silicosis. Silicosis complicated with corticosteroid-resistant autoimmune disease suggests that ASIA, an adjuvant disease, is involved in the pathogenesis. Therefore, not only SSc and SjS but also the pathogenesis of ASIA should be considered in such cases. Since adjuvant exposure is a causative factor in ASIA, avoiding such exposure is crucial.

Indexed as

AutoimmunityPleurisyScleroderma, SystemicSilicosisSjogren's SyndromeAgedFatal OutcomeHumansMale

Identifiers

PMID40319350
PMCPMC12060736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.